SCHEMBL677543

SCHEMBL677543

[CH2]Cc1ccccc1C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 1/20 0.42
NAAA Q02083 1/20 0.42
SLC6A2 P23975 4/20 0.39
SLC6A4 P31645 4/20 0.39
SLC6A3 Q01959 3/20 0.39
PTGS2 P35354 1/20 0.38
NOS1 P29475 2/20 0.36
HTR1D P28221 2/20 0.36
HTR1B P28222 2/20 0.36
BCHE P06276 1/20 0.35
ACHE P22303 1/20 0.35
NUDT1 P36639 1/20 0.33
BACE1 P56817 1/20 0.33
CEL P19835 1/20 0.33
ADRA2A P08913 2/20 0.33
HTR1A P08908 2/20 0.33
OPRL1 P41146 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
USP2 O75604 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL674077 1.00 PTGDR2 (0.42) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL677120 0.98 SLC6A2 (0.40) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL2920689 0.94 SLC6A2 (0.40) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL2913534 0.90 SLC6A2 (0.42) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL5544918 0.85 PTGDR2 (0.41) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL7650684 0.82 SLC6A2 (0.38) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL1385528 0.82 PTGDR2 (0.39) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL7648243 0.82 PTGDR2 (0.39) PTGDR2NAAASLC6A2SLC6A4SLC6A3
Formaldehyde SCHEMBL27876727 0.81 PTGDR2 (0.44) PTGDR2NAAASLC6A2SLC6A4SLC6A3
SCHEMBL7652636 0.80 PTGDR2 (0.38) PTGDR2NAAASLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113248653-B Composition encapsulating organic light emitting device and organic light emitting device display apparatus 三星SDI株式会社 2023-05-19 CN disclosed
CN-115490814-A Composition for encapsulating organic light emitting diode and organic light emitting diode display device 三星SDI株式会社 2022-12-20 CN disclosed
CN-114671978-A Composition for encapsulating organic light emitting diode and organic light emitting diode display 三星SDI株式会社 2022-06-28 CN disclosed
CN-110872365-B Composition for encapsulating organic light emitting diode and organic light emitting diode display 三星SDI株式会社 2022-04-15 CN disclosed
CN-113248653-A Composition for encapsulating organic light emitting device and organic light emitting device display apparatus 三星SDI株式会社 2021-08-13 CN disclosed
CN-110872365-A Composition for encapsulating organic light emitting diode and organic light emitting diode display 三星SDI株式会社 2020-03-10 CN disclosed
US-9090722-B2 Chemical amplification resist composition, and mold preparation method and resist film using the same FUJIFILM CORPORATION (JP) 2015-07-28 US disclosed
CN-102532162-B 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMA CO LTD 2015-05-27 CN disclosed
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-20030134221-A1 Positive resist composition FUJI PHOTO FILM CO., LTD. 2003-07-17 US disclosed
US-20030108811-A1 Positive resist composition FUJI PHOTO FILM CO., LTD. 2003-06-12 US disclosed
US-6562849-B1 Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. SANKYO COMPANY, LIMITED (JP) 2003-05-13 US disclosed
US-20030078426-A1 Amine derivative compounds SANKYO COMPANY, LIMITED (JP) 2003-04-24 US disclosed
US-6492364-B1 Triazolo and derivatives as chemokine inhibitors TORAY INDUSTRIES, INC. (JP) 2002-12-10 US disclosed
US-20020012866-A1 Positive photoresist composition FUJIFILM CORPORATION (JP) 2002-01-31 US disclosed
EP-1167366-A1 AMINE DERIVATIVES Sankyo Company, Limited (JP) 2002-01-02 EP disclosed
CN-1293674-A Triazolo gerivatives and chemokine inhibitors containing the same as the active ingredient TORAY INDUSTRIES (JP) 2001-05-02 CN disclosed
US-6207343-B1 RESIN CONTAINING GROUPS WHICH DECOMPOSE BY THE ACTION OF AN ACID TO ENHANCE ITS SOLUBILITY IN AN ALKALINE DEVELOPING SOLUTION AND A COMPOUND WHICH GENERATES AN ACID UPON IRRADIATION WITH ACTINIC RAYS OR RADIATION FUJI PHOTO FILM CO., LTD. (JP) 2001-03-27 US disclosed
EP-1067130-A1 TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT TORAY INDUSTRIES, INC. (JP) 2001-01-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030078426-A1 Amine derivative compounds H1-10, APOB, PRMT1 PTGDR2 3866/4885NAAA 515/4885SLC6A2 1969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.